Drug News
For patients with non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, erlotinib is active, and treatment beyond progression is feasible and may delay salvage therapy in selected patients, according to a study published online in JAMA Oncology.
Drug News
In study, the immune-based therapy beat docetaxel with fewer side effects
Drug News
For patients with non-small-cell lung cancer, treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is associated with skin toxic effects, according to a research letter study published online in JAMA Dermatology.
Drug News
For patients with metastatic squamous non-small-cell lung cancer (SQ NSCLC), nivolumab has been granted U.S. Food and Drug Administration approval.
Drug News
Stage IV nonsmall-cell lung cancer (NSCLC) patients in the United States often receive more radiation therapy than recommended.
Drug News
A new study has identified significant differences between non-small-cell lung cancer patients who smoke and those who don't.
Drug News
In a recent study, patients with metastatic nonsquamous non-small-cell lung cancer treated with nivolumab lived an average of 12.2 months, while patients treated with docetaxel lived an average of 9.4 months.
Drug News
Diacetylspermine identified as serum biomarker; has additive performance with pro-surfactant protein B
Drug News
Nonsmokers account for a growing percentage of aggressive lung cancer cases in the United States and the United Kingdom, new research finds.
Drug News
For some, but not all, nonmelanoma cancers, BRAF V600 is a targetable oncogene, with activity seen in non-small-cell lung cancer and Erdheim-Chester disease and Langerhans'-cell histiocytosis.
